Transcription/NN
factors/NNS
as/IN
targets/NNS
for/IN
oxidative/JJ
signalling/NN
during/IN
lymphocyte/NN
activation/NN
./.

We/PRP
previously/RB
have/VBP
demonstrated/VBN
a/DT
requirement/NN
for/IN
oxidative/JJ
events/NNS
during/IN
cell/NN
cycle/NN
entry/NN
in/IN
T/NN
lymphocytes/NNS
and/CC
have/VBP
hypothesised/VBN
that/IN
reactive/JJ
oxygen/NN
species/NNS
may/MD
act/VB
as/IN
intracellular/JJ
signalling/VBG
agents/NNS
during/IN
lymphocyte/NN
activation/NN
./.
=====
In/IN
the/DT
current/JJ
study/NN
,/,
cysteamine/NN
,/,
an/DT
aminothiol/NN
compound/NN
with/IN
antioxidant/JJ
activity/NN
,/,
has/VBZ
been/VBN
used/VBN
to/TO
further/RB
investigate/VB
the/DT
role/NN
of/IN
oxidative/JJ
signalling/NN
during/IN
lymphocyte/NN
activation/NN
./.
=====
Treatment/NN
of/IN
normal/JJ
human/JJ
peripheral/JJ
blood/NN
lymphocytes/NNS
with/IN
cysteamine/NN
in/FW
vitro/FW
was/VBD
found/VBN
to/TO
inhibit/VB
proliferation/NN
in/IN
a/DT
dose-dependent/JJ
manner/NN
,/,
with/IN
essentially/RB
complete/JJ
inhibition/NN
occurring/VBG
at/IN
a/DT
dose/NN
of/IN
400/CD
microM/NN
./.
=====
This/DT
inhibitory/JJ
effect/NN
was/VBD
limited/JJ
to/TO
the/DT
first/JJ
2/CD
h/NN
after/IN
mitogenic/JJ
activation/NN
,/,
localizing/VBG
the/DT
time-frame/NN
of/IN
action/NN
of/IN
cysteamine/NN
to/TO
within/IN
the/DT
commitment/NN
period/NN
./.
=====
It/PRP
therefore/RB
was/VBD
of/IN
interest/NN
to/TO
establish/VB
which/WDT
,/,
if/IN
any/DT
,/,
commitment/NN
events/NNS
were/VBD
affected/VBN
by/IN
oxidative/JJ
signalling/NN
during/IN
cell/NN
cycle/NN
entry/NN
./.
=====
Taking/VBG
the/DT
IL-2/NN
gene/NN
as/IN
a/DT
candidate/NN
,/,
we/PRP
examined/VBD
the/DT
effect/NN
of/IN
cysteamine/NN
treatment/NN
on/IN
early/JJ
gene/NN
expression/NN
during/IN
lymphocyte/NN
activation/NN
,/,
and/CC
on/IN
the/DT
activity/NN
of/IN
transcription/NN
factors/NNS
AP-1/NN
,/,
NF-kappa/NN
B/NN
,/,
NF-AT/NN
and/CC
Oct1/NN
,/,
whose/WP$
functions/NNS
are/VBP
required/VBN
for/IN
expression/NN
of/IN
the/DT
IL-2/NN
mRNA/NN
./.
=====
Cysteamine/NN
treatment/NN
inhibited/VBD
both/CC
expression/NN
of/IN
the/DT
IL-2/NN
mRNA/NN
and/CC
secretion/NN
of/IN
IL-2/NN
into/IN
the/DT
culture/NN
medium/NN
./.
=====
The/DT
inhibitory/JJ
effect/NN
of/IN
cysteamine/NN
may/MD
be/VB
mediated/VBN
at/IN
least/JJS
in/IN
part/NN
by/IN
an/DT
effect/NN
on/IN
transcription/NN
factor/NN
function/NN
,/,
as/IN
the/DT
DNA/NN
binding/NN
activities/NNS
of/IN
AP-1/NN
and/CC
NF-kappa/NN
B/NN
extracted/VBN
from/IN
mitogen-stimulated/JJ
cells/NNS
were/VBD
significantly/RB
inhibited/VBN
by/IN
cysteamine/NN
treatment/NN
./.
=====
Interestingly/RB
,/,
Oct1/NN
and/CC
NF-AT/NN
DNA/NN
binding/NN
activity/NN
were/VBD
not/RB
affected/VBN
by/IN
cysteamine/NN
treatment/NN
,/,
suggesting/VBG
that/IN
oxidative/JJ
signalling/NN
processes/NNS
operate/VBP
in/IN
a/DT
selective/JJ
manner/NN
./.
=====
The/DT
identification/NN
of/IN
regulatory/JJ
proteins/NNS
,/,
such/JJ
as/IN
transcription/NN
factors/NNS
,/,
as/IN
molecular/JJ
targets/NNS
for/IN
oxidative/JJ
signalling/NN
provides/VBZ
further/JJ
evidence/NN
to/TO
implicate/VB
oxidative/JJ
signalling/NN
as/IN
being/VBG
intimately/RB
involved/VBN
in/IN
the/DT
G0/NN
to/TO
G1/NN
phase/NN
transition/NN
in/IN
T/NN
lymphocytes/NNS
./.